BOSTON--(BUSINESS WIRE)--PureTech to Present at Jefferies 2019 London Healthcare Conference
09:00
东京和瑞士巴塞尔和德国曼海姆--(BUSINESS WIRE)--(美国商业资讯)--IT和网络技术领导者NEC Corporation (NEC; TOKYO: 6701)和专注于开发口服T细胞免疫治疗药物的瑞士/德国生物技术公司VAXIMM AG今天宣布，两家公司已签署临床试验战略合作协议和股权投资协议，以开发新型个体化新抗原癌症疫苗。 按合作协议条款（对双方均为非排他性），NEC将向一项I期临床试验提供资金。NEC和VAXIMM将合作开发个体化癌症疫苗，采用NEC用于其新抗原预测系统的尖端人工智能(AI)技术和VAXIMM的专利T细胞免疫治疗药物技术。一项I期临床试验将评估上述疫苗用于各类实体瘤。VAXIMM 将负责开展该临床试验，预计于2020年启动。 NEC拥有该项目的全球开发和商业化期权，但不包括中国以及日本以外的其他亚洲地区。 NEC Corporation高级副总裁Osamu Fujikawa表示：“癌症一直是最严重的医疗保健挑战之一，全球每年新诊断病例达数百万。NEC的核心技术完美定位于个体化医疗，我们坚定承诺向癌症患者交付有效治疗药物。我们很高兴与VAXIMM合作
08:01
東京和瑞士巴塞爾和德國曼海姆--(BUSINESS WIRE)--(美國商業資訊)--IT和網路科技領導者NEC Corporation (NEC; TOKYO: 6701)和專注於開發口服T細胞免疫療法的瑞士/德國生物科技公司VAXIMM AG今天宣佈，兩家公司已簽署臨床試驗策略性合作協定和股權投資協議，以開發新型個人化新生抗原癌症疫苗。 按合作協定條款（對雙方均為非排他性），NEC將為第一期臨床試驗提供資金。NEC和VAXIMM將共同開發個人化癌症疫苗，採用NEC用於其新生抗原預測系統的尖端人工智慧(AI)技術和VAXIMM的專利T細胞免疫療法技術。第一期臨床試驗將評估上述疫苗用於各類實體腫瘤。VAXIMM 將負責進行該臨床試驗，可望於2020年啟動。 NEC擁有該專案的全球開發和商業化選擇權，但不包括中國以及日本以外的其他亞洲地區。 NEC Corporation資深副總裁Osamu Fujikawa表示：「癌症一直是最嚴重的醫療保健挑戰之一，全球每年新診斷的病例達數百萬。NEC的核心技術有利於個人化醫療的發展，我們堅定致力於為癌症病患提供有效的治療藥物。我們很高興能與VAXI
08:01
MÜNCHEN--(BUSINESS WIRE)--Die Daiichi Sankyo Europe GmbH („Daiichi Sankyo“) hat heute die Veröffentlichung der Ergebnisse der Phase-3-Studie CLEAR Wisdom im Journal of the American Medical Association (JAMA) bekannt gegeben.1 Die Zulassung von Bempedoesäure wird derzeit von der Europäischen Arzneimittel-Agentur (EMA) und der US-amerikanischen Arzneimittelbehörde FDA geprüft. CLEAR Wisdom, eine doppelblinde, randomisierte Phase-3-Studie, prüft die Wirksamkeit, Langzeitsicherheit und Verträglichk
07:20
SAN DIEGO--(BUSINESS WIRE)-- #biotech--COI Pharmaceuticals, the Community Of Innovation established by Avalon Ventures, today announced the acquisition of Calporta Therapeutics by Merck.
07:00
TOKIO & BASEL, Zwitserland & MANNHEIM, Duitsland--(BUSINESS WIRE)--NEC Corporation (NEC; TOKIO: 6701), een leider in IT- en netwerktechnologieën, en VAXIMM AG, een Zwitsers / Duits biotechbedrijf gericht op de ontwikkeling van orale T-cellen immunotherapieën. Zij kondigde vandaag aan dat de bedrijven een strategische samenwerkingsovereenkomst voor klinische proeven en een investeringsovereenkomst voor aandelen hebben ondertekend om nieuwe gepersonaliseerde neo-antigeen-vaccins te ontwikkelen....
05:18
CAMBRIDGE (Massachusetts) y OSAKA (Japón)--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) anunció hoy que presentará un total de 29 abstracts patrocinados por la empresa en la 61.° Reunión Anual de la Sociedad Americana de Oncología (ASH, American Society of Hematology) del 7 al 10 de diciembre de 2019 en Orlando (Florida), que destacarán el compromiso de la empresa en el avance del tratamiento para cánceres hematológicos y trastornos de la sangre. Una búsqueda por
04:21
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial grow
02:24
MENLO PARK, Calif.--(BUSINESS WIRE)-- #personalis--Personalis, Inc. Expands Oncology Portfolio with the Launch of Cancer Whole Genome Sequencing Services
00:30
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the ownership of certain technology used by Daiichi Sankyo in its metastatic breast cancer drug candidate (DS-8201, [Fam-] trastuzumab deruxtecan), among other product candidates. Seattle Genetics contends that the linker and other ADC technology used in these drug c
00:15
MONACO DI BAVIERA--(BUSINESS WIRE)-- L’acido bempedoico riduce significativamente il livello di colesterolo LDL aggiungendosi all’effetto della terapia statinica, come mostrano i risultati della sperimentazione clinica CLEAR Wisdom, pubblicati sul Journal of the American Medical Association Daiichi Sankyo Europe GmbH (di seguito, ‘Daiichi Sankyo’) oggi ha annunciato la pubblicazione dei risultati della sperimentazione clinica CLEAR Wisdom di fase 3 sul Journal of the American Medical Associati
00:12
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating results for the third quarter ended September 30, 2019. Lineage management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2019 financial results and to provide a business update....
Tue Nov 12, 2019 23:05
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2019. PolarityTE will host a conference call and webcast today, November 12, 2019 at 4:30pm ET. Please see details below. Highlights Total revenues were $1.395 million in Q3:19, an increase of 5% compared to Q2:19 SkinTE revenues were $839 thousand in Q3:19, an inc
Tue Nov 12, 2019 23:05
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the quarter ended September 30, 2019 and provided a corporate update. “Since the beginning of the third quarter, we have realized substantial progress advancing our diverse pipeline of four clinical-stage prog
Tue Nov 12, 2019 23:05
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced financial results for the third quarter 2019 and provided an update on its business. “The GAIN Trial has been met with enthusiasm from the Alzheimer’s clinical and patient communities since its launch
Tue Nov 12, 2019 23:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX #DesignedforLIFE--Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results
Tue Nov 12, 2019 23:02
LAVAL, Québec--(BUSINESS WIRE)--Altasciences è lieta di annunciare la nomina di Martin Poirier, M.Sc., a direttore senior di Bioanalytical Sciences, con sede presso la struttura preclinica di Altasciences a Seattle, WA. Poirier metterà a frutto la sua approfondita competenza ed esperienza per guidare i clienti interni ed esterni in ogni fase dei loro progetti per le analisi in campo biologico e dell'immunomodulazione. L'eccellente reputazione di Poirier nel settore e la sua specializzazione nel
Tue Nov 12, 2019 19:52
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, una società privata incentrata sulla scoperta e sviluppo di farmaci per trattamenti rivoluzionari di patologie infiammatorie e neurologiche dalle esigenze urgenti non soddisfatte, ha oggi annunciato che la dirigenza interverrà con una presentazione alla 31a edizione della Annual Healthcare Conference, che si svolgerà a New York, NY, dal 3 al 5 dicembre. Il Dott. Michael Bozik, presidente e CEO di Knopp Biosciences, terrà una presentazione mart
Tue Nov 12, 2019 19:38
MÜNCHEN--(BUSINESS WIRE)--Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the JAMA
Tue Nov 12, 2019 19:37
TOKIO & BASEL, Schweiz & MANNHEIM, Deutschland--(BUSINESS WIRE)--Die NEC Corporation (NEC; TOKYO: 6701), ein führender Anbieter von IT- und Netzwerktechnologien, und die VAXIMM AG, ein schweizerisch-deutsches Biotech-Unternehmen, das sich auf die Entwicklung oraler T-Zell-Immuntherapien konzentriert, gaben heute bekannt, dass die Unternehmen einen strategischen Kooperationsvertrag für klinische Studien und eine Beteiligungsvereinbarung zur Entwicklung neuartiger, personalisierter Neoantigen-Kre
Tue Nov 12, 2019 19:34
TOKIO y BASILEA, Suiza y MANNHEIM, Alemania--(BUSINESS WIRE)--NEC Corporation (NEC; TOKIO: 6701), líder en tecnologías de la información y redes, y VAXIMM AG, una compañía de biotecnología suiza/alemana enfocada en el desarrollo de inmunoterapias orales de células T, anunciaron hoy que las compañías suscribieron un acuerdo de colaboración de ensayo clínico estratégico y un acuerdo de inversión de capital para desarrollar nuevas vacunas personalizadas contra el cáncer de neoantígeno. Según los t
Tue Nov 12, 2019 19:20
TOKYO & BÂLE, Suisse & MANNHEIM, Allemagne--(BUSINESS WIRE)--NEC Corporation (NEC ; TOKYO : 6701), un leader en technologies TI et réseau, et VAXIMM AG, une société de biotechnologie suisse/allemande, axée sur le développement d’immunothérapies des lymphocytes T, orales, a annoncé aujourd’hui que les sociétés avaient signé un accord de collaboration d’essai clinique, stratégique, ainsi qu’un accord de placement en actions dans le but de développer de nouveaux vaccins anticancéreux néoantigènes
Tue Nov 12, 2019 19:09
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, une société privée spécialisée dans la découverte et le développement de médicaments destinés au traitement des maladies immunologiques et neurologiques à haut risque, a annoncé aujourd'hui que la direction présentera lors de la 31ème Piper Jaffray Annual Healthcare Conference qui se tiendra à New York, NY, du 3 au 5 décembre. Michael Bozik, M.D., président et PDG de Knopp Biosciences, fera une présentation le mardi 3 décembre à 8h10, heure de
Tue Nov 12, 2019 18:57
LAVAL (Quebec/Kanada)--(BUSINESS WIRE)--Altasciences gibt die Berufung von Martin Poirier, M.Sc., zum Senior Director des Bereichs Bioanalytical Sciences bekannt. Er wird in der Einrichtung für präklinische Forschung von Altasciences in Seattle (Washington/USA) tätig sein und seine umfangreichen Kenntnisse und Erfahrungen einbringen, um interne und externe Kunden bei ihren Projekten in den Bereichen Bioanalyse und Immunmodulationsanalyse zu betreuen. Martin Poirier kann ein hervorragendes fachl
Tue Nov 12, 2019 18:39
LAVAL, Québec--(BUSINESS WIRE)--Altasciences est ravie d’annoncer la nomination de Martin Poirier, M.Sc., au poste de directeur principal de Bioanalytical Sciences ; il sera basé dans le centre préclinique d’Altasciences à Seattle, dans l'État de Washington. M. Poirier mettra en pratique ses connaissances approfondies et sa vaste expérience pour guider les clients internes et externes tout au long de leurs projets de bioanalyse et d’analyse de l'immunomodulation. La réputation exceptionnelle de
Tue Nov 12, 2019 18:14
MUNICH--(BUSINESS WIRE)--Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the JAMA
Tue Nov 12, 2019 18:08
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, una compañía privada de descubrimiento y desarrollo de medicamentos para tratamientos revolucionarios de enfermedades inflamatorias y neurológicas con necesidades no satisfechas, ha anunciado hoy que el equipo gerente se presentará en la 31ª conferencia anual sobre salud de Piper Jaffray, que se tendrá lugar en Nueva York, NY del 3 al 5 de diciembre. Está previsto que Michael Bozik, doctor en medicina, presidente y CEO de Knopp Biosciences, ha
Tue Nov 12, 2019 17:28
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, een particulier bedrijf voor het ontdekken en ontwikkelen van geneesmiddelen dat is gericht op het leveren van doorbraakbehandelingen voor immunologische en neurologische aandoeningen waaraan grote onvervulde behoeften zijn. Dit bedrijf heeft vandaag aangekondigd dat het management aanwezig zal zijn op de Piper Jaffray 31st jaarlijkse gezondheidsconferentie die zal worden gehouden in New York, NY op 3-5 december. Michael Bozik, M.D., President
Tue Nov 12, 2019 17:25
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, ein privat geführtes Unternehmen im Bereich der Entdeckung und Entwicklung von Medikamenten, das sich auf die Bereitstellung bahnbrechender Behandlungsformen für immunologische und neurologische Erkrankungen mit hohem Bedarf konzentriert, gab heute bekannt, dass das Management auf der 31. Annual Healthcare Conference von Piper Jaffray, die vom 3. bis 5. Dezember in New York, NY, stattfindet, präsentieren wird. Dr. Michael Bozik, President und
Tue Nov 12, 2019 17:20
BOSTON & SPRINGFIELD, Mass.--(BUSINESS WIRE)-- #AI--Baystate Health and Life Image announce partnership to develop AI tools to improve treatment decisions and match cancer patients to clinical trials.
Tue Nov 12, 2019 16:02
NEW YORK--(BUSINESS WIRE)-- #Marburg--The award builds on IAVI’s expertise in VSV vector technology developed through its VSV HIV vaccine candidate and VSV Lassa fever vaccine candidate.
Tue Nov 12, 2019 16:00
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) will share gender-focused real world aortic treatment insights at the 46th Annual VEITHsymposium in New York.
Tue Nov 12, 2019 15:52
INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have stabilised
Tue Nov 12, 2019 15:36
DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has completed enrollment for both ongoing global Phase 3 VIOLET clinical trials for VT-1161 ahead of schedule, advancing timelines for the company’s pivotal studies. VT-1161, an oral antifungal product candidate, is being developed for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for
Tue Nov 12, 2019 15:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for mavorixafor (X4P-001) for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficien
Tue Nov 12, 2019 15:30
LAVAL, Quebec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to announce the appointment of Martin Poirier, M.Sc., as Senior Director of Bioanalytical Sciences, based in Altasciences’ preclinical facility in Seattle, WA. Martin will apply his extensive knowledge and experience to guide internal and external clients throughout their bioanalysis and immunomodulation analysis projects. Martin’s outstanding industry reputation and specialization in the field of immunology, as well as more...
Tue Nov 12, 2019 15:28
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received Health Canada approval of CABOMETYX® (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. “Liver cancer is the fourth leading cause of cancer-related death globally, and there is an urgent need for more treatment options for patients living with this aggressive disease,”
Tue Nov 12, 2019 15:02
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the third quarter ended September 30, 2019 and provided an overview of the Company’s recent developments. “On behalf of the UroGen team, we are very pleased to announce that we have completed the New Drug Application (NDA) submission for UGN-101 to the FDA. This is a very important milestone fo
Tue Nov 12, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent accomplishments and upcoming events. “At Syros, we are focused where we believe we have the greatest potential to make a profound difference for patients by developing small-molecule medicines to control the expression of genes,” said Nanc
Tue Nov 12, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent. “Dr. Ro
Tue Nov 12, 2019 15:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City. AtriCure’s management is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting t
Tue Nov 12, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today reported financial results for the third quarter ended September 30, 2019. The Company will host a conference call today, Tuesday, November 12, 2019, at 9:00 a.m. Eastern Time to discuss its third quarter 2019 financial results and recent business highlights. Akebia also announced th
Tue Nov 12, 2019 14:57
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, presented new preclinical data on ALPN-101, a first-in-class dual CD28/ICOS antagonist for the treatment of autoimmune/inflammatory diseases, at the 2019 American College of Rheumatology Annual Meeting (ACR) in Atlanta, GA. ALPN-101 is designed to inhibit two key costimulatory pat
Tue Nov 12, 2019 14:30
NEW YORK--(BUSINESS WIRE)--IVERIC bio today provided an overview of the Company’s financial results for the third quarter 2019 and provided a general business update.
Tue Nov 12, 2019 14:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported financial results for the third quarter of 2019 and provided an update on regulatory activities related to Vicinium. “The third quarter of 2019 marked a pivotal period for the Company, as we began preparations to transition from a development stage to a commercial stage organization,” said Dr. Thomas
Tue Nov 12, 2019 14:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamer’s investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors. Collaboration with Merck Under
Tue Nov 12, 2019 14:00
NEW YORK--(BUSINESS WIRE)--IVERIC bio provided further clinical details and its development strategy for Zimura for the treatment of geographic atrophy secondary to dry AMD.
Tue Nov 12, 2019 14:00
WOODCLIFF LAKE, N.J--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three- and nine-month periods ended September 30, 2019. Third quarter and recent highlights include: Invested $12 million in research and development and external legal costs to advance Eagle’s pipeline. Eagle’s Japanese marketing partner, SymBio Pharmaceuticals Limited, submitted a New Drug Application (“NDA”) for TREAKISYM, bendamustine ready-to
Tue Nov 12, 2019 13:51
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic arthritis (JIA) will be presented for the first time during a late-breaking oral presentation at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting (November 8-13, Atlanta, GA). The study of tofacitinib in JIA is investigativ
Tue Nov 12, 2019 13:45
TÓQUIO, BASILEIA, Suíça e MANNHEIM, Alemanha--(BUSINESS WIRE)--A NEC Corporation (NEC; TOKYO: 6701), líder em tecnologias de TI e rede, e a VAXIMM AG, empresa suíça-alemã de biotecnologia dedicada ao desenvolvimento de imunoterapias com células T, anunciaram hoje a assinatura de um acordo de colaboração para estudos clínicos estratégicos e um acordo de investimento de capital para desenvolver vacinas de neoantígenos inovadoras e personalizadas contra o câncer. Segundo os termos do acordo de col
Tue Nov 12, 2019 13:11
PITTSBURGH--(BUSINESS WIRE)-- #Knoppbio--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5. Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, December 3rd at 8:10 a.m. Eastern...
Tue Nov 12, 2019 13:00
TOKYO e BASILEA, Svizzera e MANNHEIM, Germania--(BUSINESS WIRE)--NEC Corporation (NEC; TOKYO: 6701), leader in tecnologie di rete e IT, e VAXIMM AG, una società biotecnologica svizzera/tedesca concentrata sullo sviluppo di immunoterapie basate sulle cellule T orali, hanno annunciato in data odierna che le società hanno sottoscritto un accordo di collaborazione strategica per la sperimentazione clinica e un accordo di investimento azionario per sviluppare vaccini contro il cancro neoantigenici p
Tue Nov 12, 2019 11:01
BALLERUP, Denmark & CHENGDU, China--(BUSINESS WIRE)--LEO Pharma A/S and HitGen Inc. are pleased to announce that HitGen and LEO Pharma expands their collaboration with a license to develop a novel class of drugs for a dermatology indication. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening DNA encoded libraries (DEL), containing over 400 billion small molecules with drug-like properties, synthesized on a broad range of structurally dive
Tue Nov 12, 2019 09:00
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD). In the poster presentation, PXL065 was observed to hav
Tue Nov 12, 2019 09:00
If you or a loved one have gastrointestinal stromal tumors (GIST), you may want to learn more about the intrigue clinical research study. What is the purpose of the intrigue study? The purpose of the intrigue study is to evaluate an investigational drug, ripretinib (DCC-2618), as a potential new treatment option for patients living with GIST. The study is being done to learn more about the safety of ripretinib and how well it works against GIST, as compared to Sutent® (sunitinib), in patients...
Tue Nov 12, 2019 00:00
Gout StudyAttention Gout SufferersAre you looking for options for your gout? Wake Research is enrolling volunteers in a research study testing the safety and effectiveness of an investigational drug in volunteers with this condition.
Mon Nov 11, 2019 00:00
Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein levels throughout the central nervous The post Roche’s risdiplam meets primary endpoint in phase 3 SMA trial appeared first on Pharmaceutical Business review.
Tue Nov 12, 2019 15:12
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that The post NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines appeared first on Pharmaceutical Business review.
Tue Nov 12, 2019 14:12
The scope of the deal includes the acquisition of shares in Aspen Japan and associated assets held by Aspen Global. As per terms of the deal, Aspen will The post Novartis’ Sandoz to buy Aspen’s Japanese business in $441m deal appeared first on Pharmaceutical Business review.
Tue Nov 12, 2019 12:13
Entheogenix Biosciences Inc, the Delaware-based company jointly-founded as part of the venture, will leverage Cyclica’s proprietary technology to design and synthesize new compounds from psychoactive seed small molecule The post ATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders appeared first on Pharmaceutical Business review.
Tue Nov 12, 2019 11:14
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου